Jump to main content
Jump to site search

Issue 93, 2015
Previous Article Next Article

The non-innocent nature of graphene oxide as a theranostic platform for biomedical applications and its reactivity towards metal-based anticancer drugs

Author affiliations

Abstract

The self-assembly process in a solution of a mononuclear iron(II) complex based on the bispyrazolylpyridine scaffold with graphene oxide (GO) micrometer-sheets allows not only the devising of a new hybrid-architecture for GO-based materials suitable for nanomedicine, but also the unveiling of the reactive nature of GO as a drug-carrier. The neat iron complex is found to be highly active in disrupting the cell cycle through DNA binding, with behaviour and efficiency similar to that expressed by ruthenium-complexes as well as antibiotic-drugs such as doxorubicin. On the contrary, in the hybrid material the proclivity of neat GO to produce reactive oxygen species (ROS) became down-regulated by the electron-buffering properties of the loaded iron complex, evidencing the presence of an active electron transfer from the drug to GO. These findings question the use of the neat GO platform as a suitable carrier for metal-based anticancer drugs and highlight the importance of addressing the chemical/physical integrity of the drug being loaded into GO before drawing conclusions on the potential effectiveness of the hybrid material for medical applications.

Graphical abstract: The non-innocent nature of graphene oxide as a theranostic platform for biomedical applications and its reactivity towards metal-based anticancer drugs

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Jul 2015, accepted on 04 Sep 2015 and first published on 04 Sep 2015


Article type: Paper
DOI: 10.1039/C5RA13831K
Author version available: Download Author version (PDF)
Citation: RSC Adv., 2015,5, 76556-76566
  •   Request permissions

    The non-innocent nature of graphene oxide as a theranostic platform for biomedical applications and its reactivity towards metal-based anticancer drugs

    A. Mokdad, K. Dimos, G. Zoppellaro, J. Tucek, J. A. Perman, O. Malina, K. K. Andersson, K. K. Ramanatha Datta, J. P. Froning and R. Zboril, RSC Adv., 2015, 5, 76556
    DOI: 10.1039/C5RA13831K

Search articles by author

Spotlight

Advertisements